Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Shimmer Solicits Clinical Research Community Input on Expanded Open Wearables Initiative (OWEAR) Vision

10/26/2020 | 11:08am EST

As OWEAR embarks on its second year, organizers see potential to expand its positive industry impact beyond the organization’s original mission

Shimmer Research, a global leader in wearable technology for research applications, today announced that the Open Wearables Initiative (OWEAR) is evaluating a significant expansion of its vision and seeking industry input to build consensus.

OWEAR was founded in Sept. 2019 as an industry collaboration to promote the effective use of high-quality, sensor-generated measures of health in clinical research. OWEAR has already achieved much of its original vision, building a community at www.owear.org which makes open source algorithms and wearable datasets more accessible, and instituting a benchmarking program to evaluate algorithms.

“We are excited and energized by what OWEAR has been able to achieve in its first year. We also recognize that there are other meaningful ways in which OWEAR could employ open source software and collaborate to develop accepted digital endpoints,” said Geoffrey Gill, OWEAR co-founder and president of Shimmer Americas. “As OWEAR is most effective when we all work together, we decided to solicit input from the entire clinical research community to shape our expanded vision.”

OWEAR’s progress to date has been guided by its 22-member Working Group, which includes participants from Shimmer Research, Nextbridge Health, Accelting, Sage Bionetworks, DiMe, Pfizer, Merck, Eli Lilly, Novartis, Johnson & Johnson, PRA Health Sciences, Clinical Trials Transformation Initiative (CTTI) and the IEEE Standards Association.

As the OWEAR Working Group realized the extent of the industry need and desire for this level of collaboration, it began to consider additional programs. For example, it is now developing OWEAR’s first Gait Challenge, which is designed to benchmark the accuracy and reliability of gait assessment algorithms. Precise gait measurements are vitally important because they are used as a diagnostic and prognostic tool for neurological conditions, a general assessment of aging, and as a proxy for evaluating cognition. The OWEAR Gait Challenge is envisioned to act as a template for future Challenges around other wearable sensor based digital outcomes.

OWEAR’s Working Group has defined several new areas where the organization could play a pivotal role. They include providing support for developers, creating open databases, initiating broader validation efforts, and setting industry standards.

Industry stakeholders are encouraged to share their views on these potential new programs and other areas of interest with OWEAR at www.OWEAR.org. Those who would consider sponsoring the OWEAR Gait Challenge are encouraged to contact Adam Litke at alitke@shimmersensing.com to obtain additional details about the program.

About the Open Wearables Initiative (OWEAR)
OWEAR is an industry collaboration designed to promote the effective use of high-quality, sensor-generated measures of health in clinical research through the open sharing of algorithms and datasets. OWEAR serves as a community hub, indexing, distributing and benchmarking algorithms openly and transparently. It acts as a neutral broker, conducting formal, objective benchmarking processes and identifying high-performing algorithms in selected domains. Its vision is to provide the industry with a searchable database of benchmarked algorithms and source code that can be freely used by everyone to help streamline drug development and enable digital medicine. For more information, visit www.owear.org.

About Shimmer Research
Founded based on Intel technology in 2006, Shimmer Research is a well-established wearable technologies services and sensor manufacturing company based in Dublin, Ireland. In addition to standard products, Shimmer provides customized sensor development services, volume manufacturing, and complete wearable sensor solutions of any complexity. Shimmer’s technology and services have been employed by thousands of researchers at more than 900 leading companies, universities, and research institutes in more than 75 countries. Shimmer’s technology is incorporated in the products and services of more than 20 original equipment manufacturers. Shimmer has an ISO 13485:2016 certified medical devices quality management system. For more information, visit www.shimmersensing.com, https://www.linkedin.com/company/shimmer/ or follow @ShimmerSensing.

© Business Wire 2020
Latest news "Companies"
05:37pASH 2020 - AMELI-01 : Phase I, Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia
05:37pASH 2020 - PRELIMINARY RESULTS OF BALLI-01 : A Phase I Study of UCART22 in Adult Patients with Relapsed or Refractory CD22+ B-Cell Acute Lymphoblastic Leukemia
05:00pCellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting
04:45pROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Reminds K12 Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – LRN
04:28p'WELCOME HOME' : Fans finally return to Premier League
04:27pUpdated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
04:02pICPT INVESTOR FILING DEADLINE : Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Filed Against Intercept Pharmaceuticals, Inc.
04:00pBritain in 'final throw of the dice' as EU trade talks set to restart
03:59pPIRELLI & C S P A : 2020 Sakhir Grand Prix - Qualifying
03:56pRENAULT : Bottas edges out Russell for pole at Sakhir GP
Latest news "Companies"